• Agenda
    • Programs
    • Breakout Discussions
    • Short Courses
    • Plenary Keynotes
    • Speaker Biographies
    • Attendees
    • 1-on-1 Networking
    • Archives
  • Sponsor/Exhibitor
    • Attendee Demographics + Event Features
    • Sponsorship Opportunities
    • Current Sponsors
    • Exhibit Services Schedule
    • Exhibitor Prospectus
    • Lead Generation Opportunities
    • FAQs
    • Sponsor & Exhibitor Portal
  • Media
    • Media Partners
    • Downloads
    • Newsroom
    • Virtual Event Benefit Comparison
  • Posters
    • Poster Information
    • Poster Titles
  • Register
    • Event Registration
    • Group Registration
    • Press

Warning! Web API Url is not set.




Please click here to continue to the agenda for PROTACs and Targeted Protein Degradation - Part 2

Conference at a Glance pdf image

Outlook YouTube Facebook LinkedIn Twitter
#BostonDOT20

2020 Conference Programs

September 16 - 17

Target Identification and Validation – Part 1Target Identification and Validation – Part 1
RNA as a Drug TargetRNA as a Drug Target
PROTACs and Targeted Protein Degradation – Part 1PROTACs and Targeted Protein Degradation – Part 1
Lead and Candidate Selection for Therapeutic ProteinsLead and Candidate Selection for Therapeutic Proteins
Antibodies Against Membrane Protein Targets – Part 1Antibodies Against Membrane Protein Targets – Part 1
Small G ProteinsSmall G Proteins
Immunology and Oncology: Emerging Drug Targets and TherapeuticsImmunology and Oncology
Targeting NASHTargeting NASH
Disease ModelingDisease Modeling
CNS, Gene and Cell TherapyCNS, Gene and Cell Therapy

September 17 - 18

Target Identification and Validation – Part 2Target Identification and Validation – Part 2
Lead Generation StrategiesLead Generation Strategies
PROTACs and Targeted Protein Degradation – Part 2PROTACs and Targeted Protein Degradation – Part 2
Modality Selection for Next-Gen Biotherapeutics
Antibodies Against Membrane Protein Targets – Part 2Antibodies Against Membrane Protein Targets – Part 2
Kinase Inhibitor DiscoveryKinase Inhibitor Discovery
GPCR-Based Drug Discovery GPCR-Based Drug Discovery
Targeting Fibrosis
Preclinical Strategies, Models and Tools in OncologyPreclinical Strategies, Models and Tools in Oncology
Clinical and Translational BiomarkersClinical and Translational Biomarkers
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Genomics

Healthcare

IT & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers

Request Information

Privacy Policy